You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of an Osteoinductive Spinal Fusion Implant for Enhanced Fusion Rates

    SBC: Evoke Medical, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant The objective of this Phase I STTR research is to develop and test osteoinductive lumbar spinal fusion implant prototypes made using materials technology developments discovered by the PI at the University of Kansas In preliminary work lower impedance piezoelectric composite materials that generate power for direct current DC electrical stimulation applica ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. A method for accurate and sensitive detection of HIV drug-resistant minority variants

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Lipidated Stable BAM8-22 Offers a Promising Therapeutic for Neuropathic Pain

    SBC: On Target Therapeutics, LLC            Topic: 106

    DESCRIPTION provided by applicant Neuropathic pain is a serious health problem that affects millions of people worldwide and occurs in as much as of the general population The management of neuropathic pain in patients is complex with an estimated of individuals refractory to existing analgesic therapies The aging population the diabetes epidemic and the significant cohorts of can ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Non-Invasive, Highly Specific Detection of Oxytocin in Biological Fluids

    SBC: Giner, Inc.            Topic: NICHD

    DESCRIPTION provided by applicant Non Invasive Highly Specific Detection of Oxytocin in Biological Fluids Oxytocin a neuropeptide hormone plays an important role in a variety of complex social behaviors including affiliation sexual behavior and aggression It is best known for its role to facilitate the birth process through induction of myometrial muscle contractions However recent studi ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Novel therapies for inherited muscle diseases

    SBC: Medosome Biotec, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant The pursuit of novel therapies informed by the astounding advances in biomedical science of the past half century has been fruitful for many disorders However inherited muscle diseases such as muscular dystrophy remain stubbornly resistant to sophisticated molecular approaches to therapy A few therapies are finally edging towards approval but it has become ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development

    SBC: QRKANSWER LLC            Topic: NCI

    DESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Development of peptide inhibitors for neuroinflammation and neurodegeneration

    SBC: PROVAIDYA            Topic: NIA

    DESCRIPTION provided by applicant The prevalence of Alzheimerandapos s disease AD is poised to increase exponentially with the growing aging population worldwide In the United States total annual costs of AD care are projected to increase from $ billion in to over $ trillion in Paucity of disease modifying therapies capable of slowing the disease progression is an acute unmet ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Smart Residential Carpet for Promoting Aging in Place

    SBC: BioSensics LLC            Topic: NIA

    DESCRIPTION provided by applicant Aging in place or the ability of older adults to continue to live safely and economically in their own residences for as long as possible is one of the key issues of modern societies Continued population growth of older adults age will lead to significant financial and logistical burdens on the nationandapos s healthcare system As the population ages ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government